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Abstract
The crucial role of tumor-associated ﬁbroblasts (TAF) in cancer
progression is now clear in non–small cell lung cancer (NSCLC).
However, therapies against TAFs are limited due to a lack of
understanding in the subtype-speciﬁc mechanisms underlying
their accumulation. Here, the mechanical (i.e., matrix rigidity)
and soluble mitogenic cues that drive the accumulation of TAFs
from major NSCLC subtypes: adenocarcinoma (ADC) and squa-
mous cell carcinoma (SCC) were dissected. Fibroblasts were cul-
tured on substrata engineered to exhibit normal- or tumor-like
stiffnesses at different serum concentrations, and critical regulatory
processes were elucidated. In control ﬁbroblasts from nonmalig-
nant tissue, matrix stiffening alone increased ﬁbroblast accumu-
lation, and this mechanical effect was dominant or comparable
with that of soluble growth factors up to 0.5% serum. The stim-
ulatory cues ofmatrix rigidity were driven by b1 integrinmechano-
sensing through FAK (pY397), and were associated with a post-
transcriptionally driven rise in b1 integrin expression. The latter
mechano-regulatory circuit was also observed in TAFs but in a
subtype-speciﬁc fashion, because SCC–TAFs exhibited higher FAK
(pY397), b1 expression, and ERK1/2 (pT202/Y204) than ADC–
TAFs. Moreover, matrix stiffening induced a larger TAF accumula-
tion in SCC–TAFs (>50%) compared with ADC–TAFs (10%–
20%). In contrast, SCC–TAFs were largely serum desensitized,
whereas ADC–TAFs responded to high serum concentration only.
These ﬁndings provide the ﬁrst evidence of subtype-speciﬁc regu-
lation of NSCLC–TAF accumulation. Furthermore, these data
support that therapies aiming to restore normal lung elasticity
and/or b1 integrin-dependent mechano regulation may be effec-
tive against SCC–TAFs, whereas inhibiting stromal growth factor
signaling may be effective against ADC–TAFs.
Implications: This study reveals distinct mechanisms underlying
the abnormal accumulation of tumor-supporting ﬁbroblasts in
two major subtypes of lung cancer, which will assist the devel-
opment of personalized therapies against these cells. Mol Cancer
Res; 13(1); 161–73. 2014 AACR.
Introduction
Non–small cell lung cancer (NSCLC) is the most frequent type
of lung cancer and includes two major histologic subtypes:
adenocarcinoma (ADC) and squamous cell carcinoma (SCC;
ref. 1). Because these NSCLC subtypes are epithelial in origin,
most previous studies have focused on neoplastic epithelial cells.
However, there is growing awareness that tumor progression
requires stromagenesis, that is, the formation of a supportive
tumor stroma (2, 3). InNSCLCandother solid tumors, the stroma
is desmoplastic, exhibiting an overabundance of tumor-associat-
ed ﬁbroblasts (TAF), type I collagen (collagen-I) and other ﬁbrotic
extracellular matrix (ECM) components, new blood vessel for-
mation, and immune cell inﬁltration (2–5). Such desmoplastic
stroma supports tumor cell growth, invasion,metastasis, and even
resistance to treatments (5, 6).
Developing therapies against stroma–carcinoma interactions
demands identifying the key mechanisms underlying cancer
stromagenesis. The current paradigm considers the lattermechan-
isms similar to those underlying generic wound repair, according
to the striking similarities between the tissue alterations found in
desmoplastic stromas and in wounds (4, 7). However, it remains
ill deﬁned whether stromagenesis is actually driven by generic
repair responses or rather by cancer subtype-speciﬁcmechanisms.
Because TAFs are themost abundant stromal cell type (6), there
is growing interest in unraveling the processes underlying TAF
accumulation during stromagenesis. In NSCLC and other cancer
types, TAFs are frequently found in an activated/myoﬁbroblast-
like phenotype that is roughly characterized by the expression of
alpha-smooth muscle actin (a-SMA) and the enhanced deposi-
tion of ﬁbrotic ECM components. In the current paradigm, TAF
accumulation is assumed to be largely driven by paracrine signals
secreted by cancer cells or inﬁltrated immune cells as in generic
repair processes (3, 8–10). However, two lines of evidence suggest
that mechanical cues provided by the abnormal tissue hardening
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of desmoplastic tumorsmay also contribute to TAF accumulation.
First, increasing the rigidity of culture substrata enhances the
effects of exogenous growth factors on the survival and/or pro-
liferation of ﬁbroblasts from nonmalignant tissues (11–13).
Second, a marked increase in matrix rigidity is expected in the
stroma of NSCLC, because two hallmarks of desmoplastic
tumors—abundant collagen-I ﬁbers and a-SMAþ ﬁbroblasts—
have been associated with dramatic tissue hardening (14–17).
We sought to determine towhat extent extracellularmechanical
and soluble mitogenic cues regulate the accumulation of TAFs
frombothmajorNSCLC subtypes (ADCandSCC).We found that
the accumulation of ADC–TAFs in culture was mostly driven by
exogenous growth factors, in agreement with a generic repair
response. In contrast, the accumulation of SCC–TAFs largely
required matrix stiffening, whereas it was poorly responsive to
exogenous growth factors irrespective to their concentration. We
also identiﬁed the critical role of b1 integrin mechano-receptors
and delineated additional keymolecular aspects of the regulatory
role of matrix rigidity on ﬁbroblast density.
Materials and Methods
Tissue samples and primary human lung ﬁbroblasts
Tissues were collected from 21 resected patients with stage I/
II NSCLC at the Hospital Clinic de Barcelona (HCB; 10 ADC
and 11 SCC). The study was approved by the Ethics Commit-
tees of the HCB and the Universitat de Barcelona, and all
patients gave their informed consent. Selected patients were
male, chemo-na€ve, Caucasian, >55-years-old, and current smo-
kers. Further clinical characteristics are given in Supplementary
Table S1. Samples from tumor and paired tumor-free lung
parenchyma were collected. A fraction of each sample was
parafﬁn-embedded, and the remaining was used to isolate
ﬁbroblasts by outgrowth of tissue explants (18).
Histology
Parafﬁn-embedded samples were sliced in 2- to 4-mm sections,
deparafﬁnized and rehydrated. Tissue architecture and ﬁbrillar
collagens were visualized by hematoxylin–eosin (H&E) and 0.1%
picrosirius red in saturated picric acid (Direct Red 80; Sigma)
stainings, respectively. Immunohistochemical analyses of b1
integrin, a-SMA and Ki-67 were performed using the Bond auto-
mated immunohistochemistry system (Leica Microsystems). Pri-
mary antibodies included anti-b1 integrin (M-106; Santa Cruz
Biotechnology), anti–a-SMA (1A4; Dako), and anti–Ki-67 (MIB-
1; Dako). H&E and immuno-stainings were imagedwith a bright-
ﬁeld microscope (DM5000 B) coupled to a digital camera (DFC
500; Leica). Picrosirius red staining was imaged using polarized
ﬁlters. All image processing henceforth was carried out with
ImageJ (19). a-SMA stainings were imaged at 10 randomized
locations for each patient with a 10 objective. Each image was
color deconvoluted and the a-SMA channel was binarized to
calculate the a-SMA–positive (a-SMAþ) area fraction, which was
averaged for each patient and subsequently for all patients within
a subtype. To assess TAF density, a similar imaging procedure was
applied to H&E stainings for each patient using a 40 objective.
Fibroblast nuclei were counted in binarized images according to
preoptimized morphometric criteria, including area (16–333
mm2), circularity (0.1–0.5), and aspect ratio (2.5–15). These
criteria selected spindle-shaped nuclei, which is a common mor-
phologic approach used to identify ﬁbroblasts in H&E staining
(20). Spindle-shaped nuclei lining blood vessels were discarded.
Nuclei number per image was averaged for each patient, and
subsequently averaged for all patients in each subtype. The b1
integrin staining in ﬁbroblasts was scored in a semiquantitative
manner with methods similar to those previously reported (21).
Images of the stroma of b1 integrin stainings were acquired at 10
locations in each sample. Fibroblasts were identiﬁed using the
above-mentioned morphometric criteria. b1 integrin staining in
ﬁbroblasts was scored blind by two independent observers
according to three categories (negative, weak, and strong). In
average, 350 ﬁbroblasts were counted per sample. The percentage
of ﬁbroblasts per sample in terms of b1 integrin staining was
assessed for each category and observer (coefﬁcient of correlation
r2¼ 0.8), and averaged to render the ﬁnal category percentage per
histologic subtype.
Polyacrylamide gels
Collagen-I–coated polyacrylamide (PAA) gels were obtained as
reported elsewhere (11, 22). In brief, gelswere prepared bymixing
variable ratios of acrylamide (AA)/bis-acrylamide (BIS; Bio-Rad)
to exhibit normal- (3% AA:0.22% BIS) or tumor-like (12%
AA:0.45% BIS) Young's modulus. After polymerization, the gel
surface was derivatized with Sulfo-SANPAH (Thermo Scientiﬁc)
and coated with 0.1mg/mL collagen-I (Millipore). Matrix rigidity
was assessed by atomic forcemicroscopy (22, 23) as 0.6 0.1 and
28 4 kPa for normal- and tumor-like gels, respectively (mean
SD).
Cell culture
The human ﬁbroblast cell line CCD-19Lu (ATCC) and primary
ﬁbroblasts were maintained in culture medium described else-
where (18) supplemented with 1X insulin–transferrin–selenium
(ITS; Gibco). Fibroblasts were used up to passage 10 (CCD-19Lu)
or 6 (primary). Mouse embryonic ﬁbroblasts (MEF) from wild-
type (FAKþ/þ) or FAK-deﬁcient (FAK/) mice were isolated and
cultured as previously reported (24). FAKþ/þ MEFs were trans-
duced by adenoviral infection with either wild-type FAK (Adv-
FAK) or an empty vector (Adv-empty; used as control) as
described elsewhere (24). Cells were cultured for 5 days unless
otherwise indicated. For PAA gel experiments, lung ﬁbroblasts
were seeded at 8  103 cells/cm2 in serum-free culture medium
(SFM) supplemented with 0.25 mmol/L ascorbic acid (Sigma) at
different FBS concentrations. MEFs were cultured in the same
conditions by plating either 1.45 104 cells/cm2 (FAKþ/þ) or 2.8
 104 cells/cm2 (FAK/). In 2D experiments, cells were seeded in
collagen-I–coated tissue culture plastic substrata. In some experi-
ments, ﬁbroblasts were plated in the presence of the monoclonal
b1 integrin activity inhibitory antibody AIIB2 (kindly provided by
Dr. Weaver at UCSF, San Francisco, CA), the monoclonal b1
integrin–activating antibody TS2/16 or the control IgG1 antibody
(BD Biosciences).
Cell density and spreading
The nuclei of living ﬁbroblasts were ﬂuorescently labeled with
Hoechst 33342 (Molecular Probes). Fluorescence images were
acquired with an Eclipse TE2000 microscope (Nikon) at nine
randomized locations with an EM-CCD C9100a camera (Hama-
matsu) using Metamorph software (Molecular Devices) and a
10 objective. For each experiment, cell density was determined
as the average nuclear density/image and normalized to that value
obtained at 0% FBS in 1 kPa gels. To assess cell spreading, phase-
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contrast images were acquired with a similar protocol and used to
manually outline the contour of individual cells.
Proliferation and apoptosis
Proliferative activity was assessed by identifying replicating
cells with the Click-iT EdUrd Cell Proliferation Assay (Invitrogen)
following the manufacturer's instructions. Samples were incubat-
ed with 50 mmol/L EdUrd solution for 24 hours. Nuclei were
counterstained with Hoechst 33342 to assess total cell number in
each image. Fluorescence images were acquired at nine random-
ized locations with a 20 objective. For each culture condition,
EdUrd-positive cells per image were counted, normalized to the
total cell number, and averaged to obtain the ﬁnal percentage. To
assess apoptosis, cells were ﬁxed and permeabilized in the same
conditions, blocked with 0.2% Triton X-100, 1% BSA (Sigma),
and 6% FBS for 1 hour, incubated overnight with a primary
antibody against cleaved caspase-3 (Cell Signaling Technology)
at 4oC, and incubated with an anti-rabbit Cy-3 (The Jackson
Laboratory) secondary antibody for 2 hours. Fluorescence images
were obtainedwith the same protocol, background corrected, and
their total intensity (I) and cell number (N) were recorded. For
each culture condition, I versusN data were least-squares ﬁtted to
a linear function withMATLAB (Mathworks) to assess the cleaved
caspase-3 intensity per cell as the ﬁtted slope.
Western blotting
Fibroblasts were lysed in extraction buffer (62.5 mmol/L Tris-
HCl (pH 6.6), 2% SDS, 10% glycerol, and 50 mmol/L DTT)
supplemented with phosphatase (Roche) and protease inhibitors
(Cocktail Set I; Merck; Pefabloc, Roche). Equal protein amounts
were separated on a 10% Mini-PROTEAN TGX precast gels (Bio-
Rad), transferred to a polyvinylidene diﬂuoride membrane (GE
Healthcare), blocked, and incubated overnight with suitable
primary antibodies, including anti-Akt and anti-AktpS473 (9272
and 4060; Cell Signaling Technology), anti-FAK (610087; BD
Transduction Laboratories), anti-FAKpY397 (700255; Invitrogen),
anti-b1 integrin (610467; BD Biosciences), anti-Erk1/2, and anti-
Erk1/2pThr202/Tyr204 (9102 and 9101; Cell Signaling Technology),
anti-GAPDH, and anti–a-tubulin (5174 and 2144; Cell Signaling
Technology). The latter twowere used as loading controls. Protein
bands were labeled with peroxidase-conjugated stabilized goat
anti-rabbit or anti-mouse IgG (HþL; Pierce), and visualized by
chemiluminescence (SuperSignal West Pico Chemiluminescence
Substrate; Pierce) in a digital imaging system (ImageQuant LAS
4000; GE Healthcare). Protein band intensities were quantiﬁed
with Fujiﬁlm Image Gauge 4.0 software and normalized to the
corresponding loading control.
qRT-PCR
b1 integrin transcription was assessed as described elsewhere
(23) using TaqMan gene-speciﬁc primer pairs and probe (Applied
Biosystems) for genes encoding ITGB1 (Hs00559595_m1) and
POLR2A (used as a reference gene, Hs00172187_m1).
Flow cytometry
Fibroblasts were cultured in 2D in SFM for 24 hours and
stimulated without or with 10% FBS for 5 days. Cells were
trypsinized, ﬁxed with ice-cold 70% ethanol (Sigma), and spin-
dry at 2000 rpm for 10minutes. Cell pellets were stainedwith PBS
solution containing 0.5mg/mLpropidium iodide and 0.4mg/mL
ribonuclease A (RNase; Sigma). Cell-cycle analysis was performed
from DNA histograms of single cells obtained by ﬂow cytometry
(LSRFortessa; BD Biosciences) as reported elsewhere (25). The
percentages of cells in G0–G1, S, and G2–M were assessed with
FACSDiva Software v6.1.3 (BD Biosciences).
Statistical analysis
Two-group comparisons were performedwith the Student t test
(SigmaPlot) unless otherwise indicated. Statistical signiﬁcance
was assumed at P < 0.05.
Results
Desmoplastic tumor stroma accounts for 25% of the total
tumor and exhibits markers of tissue hardening in both ADC
and SCC
In normal lung parenchyma, ﬁbroblasts were sparsely located,
and a-SMAþ cells corresponding to smooth muscle cells were
largely restricted to the perivasculature (see black arrows). In
contrast, both ADC and SCC samples exhibited a stroma rich in
peritumoral a-SMAþ TAFs (Fig. 1A and Supplementary Fig. S1).
These features were used to assess the relative amount of tumor
stroma as the percentage of a-SMAþ area, which elicited approx-
imately 25% in both ADC and SCC (Fig. 1B and Supplementary
Fig. S2). Conversely, morphometric analysis revealed that TAF
density was approximately 1.5-fold higher in ADC than in SCC
(Fig. 1C and Supplementary Fig. S3). Ki-67 staining could not
unambiguously unravel whether the latter difference was due to
differential proliferation of resident ﬁbroblasts or to other pro-
cesses (Supplementary Fig. S4; ref. 26). Nonetheless, these results
suggest that TAF accumulation may be driven—at least in part—
by subtype-speciﬁc mechanisms. We further analyzed the stroma
by examining the content of ﬁbrillar collagens (Fig. 1A). Normal
lung parenchyma exhibited weak collagen staining and short
collagen ﬁbers, whereas tumor samples from both ADC and SCC
exhibited abundant collagen staining that was frequently orga-
nized into long and straight ﬁbril bundles indicative of mechan-
ical tension. Likewise, ﬁbril bundles were often organized in a
parallel fashion (see dashed squares), which has been previously
shown to render stiffer tissues (16).
Matrix stiffening alone is sufﬁcient to increase the density of
CCD-19Lu ﬁbroblasts
We engineered culture substrata based on PAA gels to mimic
normal (1 kPa) and desmoplastic (30 kPa)mechanicalmicro-
environments (Fig. 2A), and used them to examine the relative
effects of matrix stiffening and serum stimulation on cell density
in CCD-19Lu ﬁbroblasts. Although PAA gels are somewhat lim-
ited in that they provide a 2D rather than 3D microenvironment,
their physiopathologic relevance has been extensively validated
(22, 27, 28). After 5 days in culture, the normalized cell density
(D) rose with serum concentration according to an exponential
function (r2 > 0.99) in both 1 kPa (dashed) and 30 kPa gels (solid
line; Fig. 2B and Supplementary Material). However, cell density
data were consistently higher in 30 kPa than in 1 kPa gels for all
FBS (%) values. To compare quantitatively the effects of mechan-
ical and solublemitogenic cues, we assessed the relative ﬁbroblast
accumulation (R) by computing the percentage of increase in cell
density due to matrix stiffening or serum stimulation using either
the latter exponential ﬁttings (lines) or the experimental data
(white squares; Fig. 2C). The stiffening-induced ﬁbroblast accu-
mulation (Rstiffening) was 20% for all serum concentrations,
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including 0% FBS, and exhibited a biphasic dependence with
serum that peaked at approximately 0.5% to 1% FBS. Moreover,
this stiffening-induced accumulation was dominant or compa-
rablewith that due to serum (Rserum) up to 0.5%FBS (Fig. 2C inset
and Table 1), which falls within the physiologic serum concen-
tration for ﬁbroblasts as reported elsewhere (29). To rule out that
the large stiffening-induced accumulation in SFM was not due to
the presence of insulin, cell density was measured in SFM not
supplemented with ITS. In these conditions, we still observed
approximately 20% accumulation in 30 kPa gels (Fig. 2D),
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Figure 1.
Thedesmoplastic stromaof bothADCandSCCexhibitsmarkers indicative of largemechanical tension comparedwith normal lungparenchyma.A, illustrative images
of H&E (top), a-SMA (middle), and picrosirius red (bottom) stainings of histologic samples from primary control (left), ADC (middle), and SCC (right column)
pulmonary tissue obtained with a 40 objective. Arrowheads, spindle-shaped nuclei characteristic of ﬁbroblasts. a-SMA images reveal a stroma rich in
hypercontractile myoﬁbroblasts. White dashed squares, regions with straight and parallel collagen ﬁbers indicative of mechanical tension; scale bars, 30 mm.
B, assessment of the stromal area fraction within tumor samples as the percentage of a-SMAþ area in histologic sections (n ¼ 5 patients/subtype). C, TAF
density assessed bymorphometric analysis of H&E images (n¼ 10 patients/subtype; further details in Supplementary Fig. S1–S3);  , P0.05was determined by the
Student t test.
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thereby demonstrating that matrix stiffening alone is sufﬁcient to
raise ﬁbroblast population in the complete absence of exogenous
growth factors.
Matrix stiffening drives the accumulation of CCD-19Lu
ﬁbroblasts through increased proliferation and survival in a b1
integrin–dependent fashion
To dissect the mechanisms underlying the increased ﬁbro-
blast density in 30 kPa gels, we performed a time-course
analysis of proliferative and apoptotic markers in CCD-19Lu
cells. The proliferative activity declined with time in both
rigidities, yet it was higher at 30 kPa than at 1 kPa at all time
points, with the largest difference observed at 48 hours (Fig.
2E). Conversely, caspase-3 activity was lower at 30 kPa than at
1 kPa at all times, and their difference increased over time
(Fig. 2F). The increased survival cues at 30 kPa gels were
conﬁrmed independently by the early increase in AktpS473
(Fig. 2G).
Because increased proliferation and decreased apoptosis have
been previously associated with increased cell–ECM interactions
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Figure 2.
Matrix rigidity enhances the accumulationofCCD19-Luﬁbroblasts by20% through increased proliferation and survival in SFM.A, outline of the culture assay. B, time
course of normalized cell densityDafter 5 days in culture on30 kPa (black) or 1 kPa (white dots) PAAgels in SFM supplementedwith increasing serumconcentrations.
For each matrix rigidity, data were ﬁtted to an exponential function (solid and dashed lines, see Supplementary Material for details). C, relative change in cell
density due to matrix rigidity (Rstiffening) at different FBS(%) using either the experimental data (white squares) or the ﬁttings in B (solid line). Inset, a comparison
between the ﬁbroblast accumulation due to either serum (Rserum, dashed lines) or matrix stiffening up to 0.5% FBS calculated using the ﬁttings in B (see Table 1
for further details). D, ﬁbroblast density at 1 and 30 kPa gels in SFM  ITS. Unless otherwise indicated, SFM supplemented with ITS was used in all subsequent
experiments. E and F, time course of the proliferative (E) and caspase-3 (F) activities. G, (left) representative Western blot analysis of AktpSer473, total Akt,
and GAPDH in cells cultured on 1 and 30 kPa gels for 30 minutes; (right) densitometry analysis of AktpSer473/Akt. Unless otherwise indicated, all data here
and thereafter are mean SE. Numerical results correspond to three replicates from at least two independent experiments;  , P 0.05;  , P 0.01; , P 0.005
were determined by the Student t test comparing data at 1 and 30 kPa gels.
Table 1. Relative increase in either cell density or cells entering the cell cycle of ﬁbroblasts stimulated with a larger matrix rigidity or FBS concentration (mean SE)
Stimulus A Stimulus B CCD-19Lu Control ﬁbroblasts ADC-TAFs SCC-TAFs
1! 30 kPa 0% FBS 30%a,d 41  15%a 23  7%a 52  12%a
0.1% FBS 35%a,d 46  11%a 13  2%a 54  19%a
0%! 0.1% FBS 1 kPa 12%a,d 18  9%a 14  6%a 15  2%a
30 kPa 17%a,d 27  12%a 6  4%a 11  5%a
0%! 10% FBS 2.8  106 kPac 123  31%b 125  34%b 69  39%b 13  11%b
NOTE: The relative increase in normalized cell density D due to either matrix stiffening or serumwas calculated as Rstiffening (%)¼ 100 (D30 kPa D1 kPa)/D1 kPa and
Rserum (%)¼ 100 (Dc(%)D0%FBS)/D0%FBS, respectively. The relative rise in cycling cells from0% to 10% FBSwas assessed asRcycle(%)¼ 100 (P10%FBS P0%FBS)/
P0%FBS). It should be borne in mind that Rstiffening and Rserum were measured in PAA gels, whereas Rcycle were measured in 2D cultures.
aRelative increase in cell density (Rstiffening or Rserum).
bRelative increase in cells entering the cell cycle (Rcycle).
cYoung's modulus of polystyrene used in 2D cultures (28).
dValues calculated with the ﬁttings in Fig. 2C. The values in bold were statistically signiﬁcant.
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through enhanced cell spreading (12, 30), we measured cell
spreading in CCD-19Lu ﬁbroblasts. We observed elongated and
spindle-like morphologies in both 1 and 30 kPa gels (Fig. 3A).
Likewise, the distribution of cell area values were comparable in
both stiffness conditions (Fig. 3B), further indicating that the rise
in stiffening-induced ﬁbroblast accumulation was not due to
changes in cell spreading.
Adherent cells probe the mechanochemical properties of their
surrounding ECM largely through the integrin family of a/b
heterodimeric ECMmechano receptors (22, 23). Accordingly, we
examined whether matrix rigidity altered integrin mechano sens-
ingby checking FAKpY397,which is indicative of integrin activation
and clustering, and is required for focal adhesion formation and/
or stabilization in ﬁbroblasts and other adherent cells (16, 27).
We observed an early upregulation in FAKpY397 at 30 kPa com-
pared with 1 kPa (Fig. 3C). Because ﬁbroblasts were seeded on
collagen-I–coated gels, we examined the speciﬁc involvement of
integrin collagen-I receptors. In ﬁbroblasts, these receptors
include three integrins that share the b1 subunit (a1b1, a2b1, and
a11b1; refs. 31, 32). Accordingly, we ﬁrst conducted a time-course
analysis ofb1 integrin expression byWestern blotting (Fig. 3D and
E). Protein levels of mature b1 integrin were comparable at short
times (1 hour) in both stiffnesses (Fig. 3D), indicating that the
difference in FAKpY397 between matrix rigidities was due to
increased b1 integrin mechano-sensing rather than to altered
expression. b1 integrin levels increased at longer times (>>1 hour)
in all rigidity conditions, but this increase was more pronounced
at 30 kPa (6-fold) than at 1 kPa (3-fold), with the largest
difference observed at 48 hours. To shed light on themechanisms
underlying this protein dynamics, we performed a time-course
analysis of b1 integrin mRNA (Fig. 3E). Unlike the protein level,
no signiﬁcant differences were found between the mRNA
obtained in both stiffness conditions at all time points. Likewise,
a similar ratio between mature (i.e., fully glycosylated) and
precursor (i.e., partially glycosylated) b1 integrins was observed
in 1 and 30 kPa gels up to 48 hours (Supplementary Fig. S5),
indicating that the rise in mature b1 integrin observed at 48 hours
was not due to transcriptional regulation, but rather to posttran-
scriptional processes other than enhanced glycosylation.
To check whether b1 integrins were necessary for the larger cell
density observed in 30 kPa gels, we treated CCD-19Lu ﬁbroblasts
with increasing concentrations (cinh) of the b1 integrin inhibitory
antibody AIIB2 (16, 33). We observed a dose-dependent decrease
in cell density in cells cultured in30kPa gels treatedwithAIIB2but
not with IgG1. Such decrease was well captured by an exponential
decay (solid line), eliciting cinh,50 ¼ 3.8 mg/mL (Fig. 4A). Fibro-
blasts cultured on 30 kPa gels treated with 3 mg/mL AIIB2—close
to cinh,50—downregulated both FAK
pY397 (Fig. 4B) andmature b1
integrin expression (Fig. 4C) to levels comparable with those
observed at 1 kPa. Likewise, AIIB2downregulated theproliferative
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Figure 3.
Matrix rigidity induces both increased integrin mechano-sensing through FAKpY397 and a posttranscriptionally driven rise in b1 integrin expression in CCD-19Lu
ﬁbroblasts. A, images of sparse ﬁbroblasts cultured on 1 and 30 kPa PAA gels for 24 hours; scale bars, 30 mm. B, projected area of cells cultured as in A (n > 250
cells/condition). C, (left) representative Western blot analysis of FAKpY397, total FAK, and a-tubulin in cells cultured on 1 and 30 kPa gels for 20 minutes;
(right) densitometry analysis of FAKpY397/FAK. D, (left) representative Western blot analysis showing the time-course expression of total b1 integrin and loading
control of cells cultured on 1 and 30 kPa gels; (right) densitometry analysis of the time-course expression of mature b1 integrin normalized to a-tubulin. E, time
course of b1 mRNA assessed by qRT-PCR of cells cultured as in D. Numerical data correspond to three replicates from at least two independent experiments.
Statistical analysis was performed as in Fig. 2 except in B, in which the Mann–Whitney rank-sum test was used.
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activity (Fig. 4D), whereas it upregulated cleaved caspase-3 (Fig.
4E) and reduced AktpS473 (Fig. 4F) to levels similar to those
observed at 1 kPa. On the other hand, activating b1 integrin with
5 mg/mL TS2/16 antibody—which binds b1 integrin within the
same small region than AIIB2 (34)—was sufﬁcient to increase
both cell density (Fig. 4G) and FAKpY397 expression of CCD-19Lu
ﬁbroblasts in 1 kPa gels compared with IgG1 treatment (Supple-
mentary Fig. S6). To conﬁrm further the requirement ofb1 integrin
mechano-sensing through FAKpY397 in matrix stiffening–driven
ﬁbroblast accumulation, we either depleted or overexpressed FAK
inMEFs as previously described (24). As inCCD-19Luﬁbroblasts,
matrix stiffening enhanced cell density and FAKpY397 expression
in wild-type MEFs (FAKþ/þ), whereas such increases were not
observed in FAK null ﬁbroblasts (FAK/; Fig. 4H and Supple-
mentary Fig. S6). Conversely, overexpressing FAK in wild-type
MEFswas sufﬁcient tomarkedly increase both cell density (Fig. 4I)
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Inhibition of b1 integrin or FAK depletion prevent matrix rigidity-induced accumulation of ﬁbroblasts in 30 kPa gels, whereas forcing b1 integrin activation or FAK
expression act otherwise. A, dose–response effects of b1 integrin inhibitory antibody AIIB2 and control IgG1 antibody on the density of CCD-19Lu cells cultured for 5
days on 30 kPa gels. Solid and dashed lines correspond to a ﬁtting to an exponential function and to the average of AIIB2 and IgG1 data, respectively (see
SupplementaryMaterial for details). B, (left) representativeWestern blot analysis of FAKpY397, total FAK, anda-tubulin (left) inCCD-19Lu cells cultured oneither 1 kPa
gels and treated with IgG1 or on 30 kPa gels and treated with 3 mg/mL IgG1 or AIIB2; (right) densitometry analysis of FAKpY397/FAK. C, (left) representative
Western blot analysis of total b1 anda-tubulin in cells cultured as in B for 48 hours; (right) densitometry analysis ofmature b1. D and E, proliferative (D) and apoptotic
(E) activities of CCD-19Lu cells cultured as in B for 48 hours and 5 days, respectively, assessed as in Fig. 2. F, (left) representativeWestern blot analysis of AktpSer473,
total Akt, and GAPDH (left) of cells cultured as in B; (right) densitometry analysis of AktpSer473/Akt. G, normalized cell density of CCD-19Lu ﬁbroblasts treated
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normalized cell density of FAK-overexpressing (Adv-FAK) and control (Adv-empty) wild-type MEFs. Numerical results correspond to three replicates from at least
two independent experiments. Statistical analysis was performed as in Fig. 2 by comparing each group with respect to either IgG1 at 30 kPa (A–G) or control
conditions at 1 kPa (H and I).  , P < 0.05;  , P < 0.01;  , P < 0.005.
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Figure 5.
Primary TAFs exhibit subtype-speciﬁc
aberrant responses to either matrix
rigidity or serum with respect to
primary control ﬁbroblasts. A,
normalized cell density in three classes
of primary ﬁbroblasts (control
ﬁbroblasts, ADC–TAFs, and SCC–
TAFs) cultured as in Fig. 2 in SFM or
0.1% FBS. Two-group comparisons
within classes were performed to
analyze the effect of either matrix
rigidity () or serum (þ). Statistical
analyses between classes (#) were
restricted to 30 kPa gels (n ¼ 10 for
control ﬁbroblasts; n ¼ 5 for both
ADC–TAFs, and SCC–TAFs). All P
values are shown in Supplementary
Table S2. B, the percentage of cycling
ﬁbroblasts (i.e., in S and G2–M)
cultured in 2D in SFM or 10% FBS
for 5 days (n ¼ 10 for control
ﬁbroblasts; n ¼ 6 for both ADC–TAFs,
and SCC–TAFs). C, the ratio between
percentages at 10% FBS and SFM.
D, (left) representative Western blot
analysis of Erk1/2pT202/Y204, total
Erk1/2, and loading of TAFs cultured
in 2D for 20 minutes; (right)
densitometry analysis of
Erk1/2pT202/Y204/Erk1/2 (n ¼ 3/
subtype).  , P < 0.05;  , P < 0.01;
 , P < 0.005.
Puig et al.
Mol Cancer Res; 13(1) January 2015 Molecular Cancer Research168
on September 15, 2015. © 2015 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from 
Published OnlineFirst October 3, 2014; DOI: 10.1158/1541-7786.MCR-14-0155 
and FAKpY397 expression (Supplementary Fig. S6) in 1 kPa gels
compared with control MEFs.
The accumulation of primary SCC–TAFs in culture requires
matrix stiffening, whereas that of ADC–TAFs demands high
serum concentration
To examine whether the ﬁndings obtained with CCD-19Lu
cells and MEFs could be extended to primary ﬁbroblasts, we
assessed the ﬁbroblast accumulation due to either matrix stiff-
ening or 0.1% FBS in primary NSCLC–TAFs and corresponding
control ﬁbroblasts. As in CCD-19Lu cells and MEFs, cell density
in control ﬁbroblasts was consistently higher in 30 kPa than in
1 kPa gels (Fig. 5A), and this difference was associated with
increased proliferative and decreased apoptotic activities (Sup-
plementary Fig. S7). Likewise, matrix stiffening-induced accu-
mulation increased in TAFs, yet in a subtype-speciﬁc fashion
according to SCC (>50%) > ADC (10%–20%; Table 1). In
further agreement with CCD-19Lu cells, the relative accumu-
lation due to matrix stiffening was consistently larger than that
due to 0.1% FBS in primary ﬁbroblasts (Table 1). Intriguingly,
the serum-dependent accumulation at 30 kPa gels was much
lower in TAFs than in control ﬁbroblasts or CCD-19Lu ﬁbro-
blasts, particularly in ADC–TAFs. To check whether the latter
poor serum responses were due to an impairment in cell-cycle
progression, we examined the ability of TAFs cultured in 2D to
enter the cell cycle in response to 10% FBS by ﬂow cytometry
(Fig. 5B). The percentage of cycling cells (i.e., cells that entered
into either S or G2–M) at 10% FBS with respect to 0% FBS
almost doubled in both control ﬁbroblasts and ADC–TAFs,
whereas it remained unaltered in SCC–TAFs (Fig. 5C). Indeed,
the relative rise in cycling cells from 0% to 10% FBS was
comparable with the relative accumulation of ﬁbroblasts
induced by 0.1% FBS in SCC–TAFs (Table 1), revealing a very
weak serum response in this subtype. Of note, the percentage of
cycling cells at 0% FBS in SCC–TAFs was 35% larger than that in
control ﬁbroblasts or ADC–TAFs (Fig. 5B), suggesting an intrin-
sic overactivation of mitogenic activity in the absence of exog-
enous growth factors in SCC–TAFS. In support of the latter
interpretation, we observed higher Erk1/2pT202/Y204 in SCC–
TAFs compared with ADC–TAFs in 2D (Fig. 5D). To our
knowledge, these results report for the ﬁrst time subtype-spe-
ciﬁc responses to extracellular mechanical and soluble mito-
genic cues in TAFs.
b1 integrin protein levels in vivo and in culture correlatewith the
relative increase in primary TAF accumulation in stiff substrata
The relative differences in cell density among primary TAFs and
control ﬁbroblasts observed in 30 kPa gels (Fig. 5A) were repro-
duced in 2D cultures (Fig. 6A and Supplementary Fig. S8). These
observations are in accordance with previous studies reporting
that cell behavior in 2D cultures is qualitatively similar to that
observed in stiff PAA gels, whereas it enhances quantitatively the
trends observed from soft to stiff PAA gels (11, 27). Accordingly,
we used 2D cultures to gain molecular insights underlying the
differences between ADC–TAFs and SCC–TAFs in stiff microen-
vironments. We observed higher proliferative activity in SCC–
TAFs than inADC–TAFs in2D (Fig. 6B),whereas caspase-3 activity
(Fig. 6C) and AktpS473 levels (Fig. 6D) remained comparable in
both subtypes. These results are consistent with the larger per-
centage of cycling cells and Erk1/2pT202/Y204 observed in SCC–
TAFs than in ADC–TAFs at 0% FBS, and suggest that the enhanced
matrix stiffening-induced accumulation in SCC–TAFs was driven
by increasedproliferative rather than survival cues. In addition,we
found that both FAKpY397 (Fig. 6E) and b1 expression (Fig. 6F)
followed the same trend in 2D than that of the matrix stiffening
increased ﬁbroblast accumulation (i.e., SCC > ADC). Moreover,
the differences in cell density between ADC–TAFs and SCC–TAFs
were abrogated upon treatment with 3 mg/mL AIIB2 (Fig. 6G).
These results conﬁrmed that matrix stiffening-driven ﬁbroblast
accumulation was b1 integrin dependent in TAFs, and revealed
that the higher accumulation observed in SCC–TAFs compared
with ADC–TAFs in 30 kPa gels was associated with larger b1
integrin expression and mechano-sensing through FAKpY397. In
agreement with the latter association, overexpressing FAK inwild-
type MEFs cultured in 30 kPa gels was sufﬁcient to increase
cell density by approximately 40% with respect to control
MEFs (Supplementary Fig. S9). To extend these observations to
the tissue context, we examined b1 integrin in TAFs in vivo by
immunohistochemistry. In agreement with our culture data,
image analysis revealed a higher percentage of stromal cells with
strong b1 integrin staining in SCC (50% 6%) than in ADC (36%
 2%, P ¼ 0.03) tumor samples (Fig. 6H and Supplementary
Fig. S10).
Discussion
The cancer subtype speciﬁcity of stromal desmoplastic fea-
tures remains ill deﬁned in NSCLC. We found that TAFs were
overwhelminglya-SMAþ and peritumoral in bothADC and SCC
subtypes of NSCLC, thereby extending previous observations on
lung ADC (15, 35). We also reported for the ﬁrst time that
the desmoplastic stroma accounts for approximately 25% of the
total tumor in both subtypes. Likewise, we observed two colla-
gen signatures previously associated with matrix stiffening
in both subtypes: An increased collagen amount and peritu-
moral stretched collagen ﬁbers (36). Intriguingly, despite these
similar desmoplastic features, we found amarkedly distinct TAF
density between ADC and SCC in vivo, which suggests that TAF
accumulation may be driven through subtype-speciﬁc
mechanisms.
To dissect the functional role of matrix stiffening in NSCLC
stromagenesis, we ﬁrst compared the relative contribution of
matrix rigidity and soluble mitogenic factors in the accumulation
of lung ﬁbroblasts from nonmalignant tissue. We showed for the
ﬁrst time that matrix stiffening alone was sufﬁcient to drive
ﬁbroblast accumulation by 20%, even in the absence of exog-
enous growth factors. Moreover, the effect of matrix stiffening on
ﬁbroblast density was dominant or comparable with that due to
mitogenic cues present in serum up to 0.5% FBS, which is a more
physiologic concentration than the 10% to 20%FBSused inmany
cell culture studies. All these ﬁndings strongly support that matrix
stiffening alone may be as important as soluble growth factors in
driving ﬁbroblast accumulation in vivo, thereby challenging the
current view of stromagenesis as driven by paracrine signaling
only (3, 8–10). Moreover, they extend previous evidence of a
positive feedback loop in which activated ﬁbroblasts lay out
increased amounts of ﬁbrotic ECM components that render a
stiffer ECM, which in turn may drive ﬁbroblast activation and
accumulation further (11, 14).
The mechanisms by which matrix stiffening enhances ﬁbro-
blast density had remained elusive. In ﬁbroblasts from non-
malignant tissue, we demonstrated that mechanically driven
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cell accumulation requires b1 integrin receptors. Moreover,
matrix stiffening induced an early increase in b1 integrin
mechano-sensing through FAKpY397 followed by a rise in
AktpS473, which were associated with increased proliferative
and survival activities. Further evidence for a mechanistic
relationship between b1, FAKpY397 and AktpS473 has been
Figure 6.
The larger cell accumulation, proliferative activity, integrin mechano-sensing, and b1 expression in SCC–TAFswith respect to ADC–TAFs in 2D culture are associated
with higher b1 expression of SCC–TAFs in vivo. A to D, normalized ﬁbroblast density (n ¼ 9; A), proliferation (n ¼ 6; B), apoptosis (n ¼ 6; C), and survival signaling
(n ¼ 3; D) of TAFs in 2D culture. E and F, representative Western blots and average densitometry analyses of FAK (n ¼ 3; E) and b1 integrin (n ¼ 9; F) of
TAFs in 2D culture. Assays in A to F performed as in Fig. 4. G, normalized density of TAFs in 2D culture treated with 3 mg/mL IgG1 or AIIB2 (n¼ 9 and 6, respectively).
H, (left) illustrative images of histologic b1 integrin stainings obtained with a 40 objective. Arrowheads, to ﬁbroblasts. Insets, enlarged ﬁbroblast-rich
regions within each image; scale bars, 30 mm. Additional examples and full scoring details are given in Supplementary Fig. S10. I, outline of the emerging mechano-
regulatory mechanism of ﬁbroblast accumulation. J, scheme illustrating the differential regulation of mechanical and soluble mitogenic cues in ADC–TAFs and
SCC–TAFs.  , P < 0.05;  , P < 0.01;  , P < 0.005.
Puig et al.
Mol Cancer Res; 13(1) January 2015 Molecular Cancer Research170
on September 15, 2015. © 2015 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from 
Published OnlineFirst October 3, 2014; DOI: 10.1158/1541-7786.MCR-14-0155 
previously reported in ﬁbroblasts and epithelial cells in
response to distinct mechanical stimuli in the presence of
growth factors (16, 37, 38). In contrast, we show that exoge-
nous growth factors are not required to activate this regulatory
mechanism. In addition, matrix stiffening increased mature b1
integrin levels at a later time scale (>>1 h) at the protein but not
mRNA levels. Conversely, the mechanically driven increases in
early FAKpY397 and late posttranscriptional b1 integrin were
abrogated with a b1 integrin inhibitor, whereas FAKpY397 was
enhanced with a b1 integrin–activating antibody, thereby
strongly suggesting a common regulatory process. The latter
interpretation was validated independently by genetic manip-
ulations in ﬁbroblasts in which FAK was either depleted or
overexpressed. To our knowledge, these are the ﬁrst observa-
tions that posttranscriptional integrin regulation can be driven
by matrix rigidity in ﬁbroblasts. Unraveling the molecular
complexity underlying such posttranscriptional regulation
(39, 40) will require future investigations. However, whatever
the regulatory mechanism might be, it is conceivable that the
functional role of the enhanced b1 integrin level is to reinforce
the b1/FAKpY397/AktpS473 mechano-regulatory pathway to fur-
ther stabilize focal adhesions and ﬁbroblast accumulation as
outlined in Fig. 6I.
The mechano-regulatory mechanism observed in ﬁbroblasts
from nonmalignant tissue could be somewhat extended to TAFs
(Fig. 6I), because matrix stiffening increased TAF accumulation
through b1 integrins. However, some aspects of this mechano-
regulatory pathway were different in control ﬁbroblasts than in
TAFs in a subtype-speciﬁc fashion. Thus, mechanically induced
ﬁbroblast accumulation was larger in SCC–TAFs and lower in
ADC–TAFs than control ﬁbroblasts and CCD-19Lu cells (Table
1). Likewise, we reported the novel observation of a higher b1
integrin expression in SCC–TAFs than in ADC–TAFs both in
culture and in vivo. In agreement with this ﬁnding, a larger
expression of the alpha subunits of collagen-I integrin receptors
in ﬁbroblasts (31, 32) has been reported in SCC compared with
ADC (41). The mechanisms underlying the larger b1 integrin
expression in SCC–TAFs remain unknown. However, it is
possible that the integrin regulator kindlin-2—a focal adhesion
protein involved in integrin activation through interactions
with the b subunit—may be involved, according to a recently
reported lower stromal kindlin-2 expression in SCC compared
with ADC (42).
We reported another novel subtype-speciﬁc difference in TAFs
in terms of serum response. Unlike control ﬁbroblasts, the accu-
mulation of ADC–TAFs in culture required high serum concen-
tration, whereas matrix stiffening effects were weak. In contrast,
SCC–TAFs were largely serum desensitized, revealing that their
accumulation required a stiff microenvironment (Fig. 6J). This
serum desensitization was associated with a larger Erk1/2 activa-
tion, mitogenic activity, and b1 integrin expression in SCC–TAFs
compared with ADC–TAFs in SFM, which are consistent with the
crosstalk between integrins and growth factor receptor signaling
reported elsewhere (43). The mechanisms underlying the distinct
molecular features observed in ADC–TAFs and SCC–TAFs remain
unknown. However, they could be associated with differences in
the secretome of cancer cells from these two subtypes (44). Unlike
stiff substrata, no marked differences in absolute (not normal-
ized) cell density values were observed in 1 kPa gels between
ADC–TAFs and SCC–TAFs (Supplementary Fig. S11), supporting
that the subtype-speciﬁc differences in TAF accumulation require
both extrinsic (i.e., matrix stiffening) and intrinsic (b1 integrin,
Erk1/2 activity) cues. Taken altogether, these observations chal-
lenge further the common assumption that all tumor desmoplas-
tic stromas arise through similar processes akin to generic wound
repair (4, 7).
The current paradigm of TAF accumulation based on repair-
like processes (3, 8–10) supports a therapeutic strategy to
reduce their density based on inhibiting stromal growth fac-
tors. Our data support the latter strategy in ADC–TAFs but not
in SCC–TAFs. In agreement with this hypothesis, an inhibitor
of multiple tyrosine kinases—many of which are known pro-
mitogenic effectors in ﬁbroblasts—in combination with doc-
etaxel has been recently reported to be therapeutically effective
in patients with NSCLC with advanced ADC but not with SCC
subtpype (45). In contrast, our results support a novel strategy
to target SCC–TAFs based on either restoring normal lung
elasticity and/or b1 integrin–dependent mechano regulation.
This new approach may be particularly clinically relevant
according to a recent report that SCC samples exhibit an
intratumoral pressure approximately 25% greater than ADC
(46). Of note, successful therapeutic approaches aiming to
rescue normal tissue mechano regulation have been recently
reported in animal models of ﬁbrosis and cancer (16, 47, 48),
raising the exciting possibility that these or related approaches
may be effective against SCC NSCLC.
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